Research on immunotoxins and their applications
DOI:
https://doi.org/10.61173/j85n6e95Keywords:
cancer therapy, specificity, toxin, antibodyAbstract
This article discusses the research progress and application of immunotoxins in cancer therapy. Immunotoxins, are proteins that combine a toxin with an antibody or growth factor, specifically attacking cells with a particular marker. show a high degree of specificity and lethality against cancer cells. The paper reviews the history of immunotoxins, their classification, mechanism of action and their application in the treatment of different types of cancer, emphasizing their potential to reduce immunogenicity and prolong the treatment cycle. Despite challenges such as immunogenicity in clinical applications, immunotoxins are considered to be powerful tools for future cancer therapy.
References
[1] FerlayJ,ErvikM,LamF,ColombetM,MeryL,PiñerosM,etal.Glo balCancerObservatory:CancerToday.Lyon:InternationalAgencyf orResearchonCancer;. 2020[ Lyon:InternationalAgencyforResea rchonCancer;2020[ https://gco.iarc.fr/today Lyon:InternationalA gencyforResearchonCancer;2020[ ,accessedFebruary2021].
[2] Liu, Zongchao, etal. “Interpretation of the 2020 Global Cancer Statistics Report.” Electronic Journal of Comprehensive Cancer Therapy 7.02[2021]:1- 14.
[3] MathewM,VermaRS.Humanizedimmunotoxins:ane wgenerationofimmunotoxinsfortargetedcancertherapy. CancerSci2009;100:1359-1365 .
[4] Akbari, Bahman Farajnia, Safar AhdiKhosroshahi,Shiva AhdiKhosroshahi,Shiva. Immunotoxins in cancer therapy: review and update.
[5] AllahyariH,HeidariS,GhamgoshaM,SaffarianP,AmaniJ.Imm unotoxin:Anewtoolforcancertherapy.TumorBiology.2017;39[2]. doi:10.1177/ 1010428317692226
[6] ChoudharyS,MathewM,VermaRS.Therapeuticpotentialofantic ancerimmunotoxins.DrugDiscovToday.2011;16[11-12]:495-503.
[7] KimJS,JunSY,KimYS.Criticalissuesinthedevelopmentofimmu notoxinsforanticancertherapy[J].Journalofpharmaceuticalscienc es,2020,109[1]. 104-115.
[8] MadhumathiJ,VermaRS.Therapeutictargetsandrecentadv ancesinproteinimmunotoxins[J].Currentopinioninmicrobiolo gy,2012,15[3]:300-309.
[9] TANG Hai-Shu,SUN Su-Rong.Research on immunotoxins and their applications[J]. Biological Bulletin,2008,43[11]:7-10. WangLC,KangL,HTM,etal.Abrin-aAchainexpressedassolublefor minEscherichiacolifromaPCR- synthesizedgeneiscatalyticallyan dfunctionallyactive[J].Biochimie,2004,86[4-5]:327-333.
[10] Pei Wuhong, Shen Beifen. Progress of basic and clinical research on immunotoxins. Foreign Medical Immunology, 1999, 22[6]:317-319.
[11] LiBY,RamakrishnanS.Recombinanthybridtoxinwithdualenz ymaticactivities.Potentialuseinpreparinghighlyeffectiveimmunot oxins[J]. JournalofBiologicalChemistry,1994,269[4]:2652-2658.
[12] LiuY,CheungLH,MarksJW,etal.Recombinantsingle- chainant ibodyfusionconstructtargetinghumanmelanomacellsandcontainin gtumornecrosisfactor[J].Internationaljournalofcancer,2004,108[4 ]:549-557.
[13] ChangK,PastanI.Molecularcloningofmesothelin,adiffere ntiationantigenpresentonmesothelium,mesotheliomas,andov ariancancers[J]. ProceedingsoftheNationalAcademyofScienc es,1996,93[1]:136-140.
[14] PastanI,LovelaceET,GalloMG,etal.Characterizationofmonoc Dean&Francis lonalantibodiesB1andB3thatreactwithmucinousadenocarcinomas [J]. CancerResearch,1991,51[14]:3781-3787.
[15] NagaiT,TanakaM,TsuneyoshiY,etal.Invitroandinvivoeffica cyofarecombinantimmunotoxinagainstfolatereceptorβ ontheac tivationandproliferationofrheumatoidarthritissynovialcells[J]. Arthritis&Rheumatism. OfficialJournaloftheAmericanCollegeof Rheumatology,2006,54[10]:3126-3134.
[16] ChenW,LiH,JiaY,etal.InvivoadministrationofplasmidDNAe ncodingrecombinantimmunotoxinDT390-IP- 10attenuatesexper imentalautoimmuneencephalomyelitis[J].Journalofautoimmuni ty,2007,28[1]:30-40.
[17] JiaY,LiH,ChenW,etal.Preventionofmurineexperimental autoimmuneencephalomyelitisbyinvivoexpressionofanove lrecombinantimmunotoxinDT390 -RANTES[J].Genethera py,2006,13[18]:1351-1359.
[18] EklundJW,KuzelTM.Denileukindiftitox:aconciseclinicalrevi ew[J].Expertreviewofanticancertherapy,2005,5[1]:33-38.
[19] ReGG,WatersC,PoissonL,etal.Interleukin2[IL-2]rec eptorexpressionandsensitivitytodiphtheriafusiontoxinDA B389IL- 2inculturedhematopoieticcells[J].Cancerresear ch,1996,56[11]:2590-2595.
[20] YaguraH,TamakiT,FuritsuT,etal.Demonstrationofhighaffinityinterleukin-2receptorsonB-chroniclymphocyticle ukemiacells. Functionalandstructuralcharacterization[J]. Blut,1990,60:181-186.
[21] MansfieldE,AmlotP,PastanI,etal.RecombinantRFB 4immunotoxinsexhibitpotentcytotoxicactivityforCD22- bearingcellsandtumors[J].Blood. TheJournaloftheAmericanSocie tyofHematology,1997,90[5]:2020-2026.
[22] KioiM,SeetharamS,PuriRK.TargetingIL-13Rα2-positivecan cerwithanovelrecombinantimmunotoxincomposedofasingle- cha inantibodyandmutatedPseudomonasexotoxin[J].Molecularcancer therapeutics,2008,7[6]:1579-1587.
[23] ChowdhuryPS,VinerJL,BeersR,etal.Isolationofahighaffinitystablesingle-chainFvspecificformesothelinfromDNA- im munizedmicebyphagedisplayandconstructionofarecombinantim munotoxinwithanti-tumoractivity[J]. ProceedingsoftheNationalA cademyofSciences,1998,95[2]:669-674.
[24] LeMaistreCF.DAB389IL-2[DenileukinDiftitox,ONTAK]:Ot herPotentialApplications[J].ClinicalLymphoma,2000,1:S37-S40.
[25] VanRoonJAG,VanVuurenAJ,WijngaardenS,etal.Selectiveeli minationofsynovialinflammatorymacrophagesinrheumatoidarthri tisbyanFcγ receptorI-directedimmunotoxin[J].Arthritis&Rheuma tism,2003,48[5]:1229-1238.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
